<p>The Centers for Medicare &amp; Medicaid Services announced that eligible Medicare beneficiaries living with obesity will gain access to Wegovy (semaglutide) for a $50 monthly copay beginning July 1, 2026, under the new Medicare GLP-1 Bridge program.</p>



<p>The initiative, launched in partnership with <strong>Novo Nordisk</strong> A/S (NYSE:NVO), will provide nationwide access to all doses and formulations of Wegovy injection and Wegovy pill through the end of 2027.</p>



<p>The program is aimed at expanding access to FDA-approved obesity treatment for millions of Medicare beneficiaries.</p>



<p>Eligible patients will be able to work with healthcare professionals to begin and continue treatment using semaglutide.</p>



<div>


<p>
<strong>
Read Also:

GLP-1 Boom Sparks Potential 'Bubble Effect,' Shrinking Competition In Big Pharma, Warns Deloitte: 'The Question Is…'
</strong>
</p>


</div>


<h2>Program Covers Multiple Wegovy Formulations</h2>



<p>According to the announcement on Thursday, the Medicare GLP-1 Bridge will be available across all U.S. states and territories.</p>



<p>The program includes both Wegovy injection and tablet formulations for weight management in eligible Medicare patients living with obesity.</p>



<h2>Amazon Pharmacy Expands Oral Ozempic Access</h2>



<p><strong>Amazon.com Inc.</strong> (NASDAQ:AMZN) on Thursday said its Amazon Pharmacy business is expanding access to Novo Nordisk’s oral Ozempic pill, the only FDA-approved oral GLP-1 medication for treating Type 2 diabetes, with same-day delivery and upcoming in-office pickup options.</p>



<p>Amazon Pharmacy said insured customers may pay as little as $25 per month for the medication.</p>



<p>For customers paying without insurance, pricing starts at $149 per month after manufacturer-sponsored savings are automatically applied during checkout.</p>



<h2>Same-Day Delivery Network Expands</h2>



<p>Amazon said the Ozempic pill will initially be available through its Same-Day Delivery service in nearly 3,000 cities and towns across the U.S. The company plans to expand that footprint to almost 4,500 cities and towns by the end of the year.</p>



<p>The company added that next-day, two-day, and three-day prescription delivery options will also be available in regions where traditional mail-order pharmacies can take between five and 10 days to deliver medications.</p>



<h2>One Medical Kiosks To Offer Faster Pickup</h2>



<p>The company also plans to introduce in-office pickup kiosks at select One Medical locations. </p>



<p>Amazon said the licensed pharmacist-supported kiosks will allow patients to receive the medication within minutes following medical appointments, eliminating the need to wait in pharmacy lines.</p>



<p><em>Image via Shutterstock</em></p>



<div>


<p><strong>
Read Also:

AST SpaceMobile Shares Fall: Rakuten Sells Stake, Timeline Risks Loom 
</strong></p>


</div>

AMZN

<p>The Centers for Medicare & Medicaid Services (CMS) will provide eligible Medicare patients access to Wegovy for obesity treatment at a $50 monthly copay starting July 1, 2026. This initiative, in partnership with Novo Nordisk, aims to expand access to FDA-approved obesity treatments nationwide. The program will cover all Wegovy formulations and is part of the new Medicare GLP-1 Bridge program, allowing patients to work with healthcare professionals for treatment. Additionally, Amazon Pharmacy is expanding access to Novo Nordisk’s oral Ozempic with same-day delivery options.</p>

- The Centers for Medicare & Medicaid Services will provide eligible Medicare beneficiaries with access to Wegovy (semaglutide) for obesity treatment at a $50 monthly copay starting July 1, 2026.  
- This initiative, part of the Medicare GLP-1 Bridge program in partnership with Novo Nordisk A/S, ensures nationwide access to all Wegovy formulations through 2027.  
- The program aims to enhance access to FDA-approved obesity treatments for millions of beneficiaries, allowing them to collaborate with healthcare professionals for treatment.

benzinga_article

Amazon

Novo Nordisk AS

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

SPDR S&P Health Equip

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

iShares US Medical Devices

VanEck Biotech ETF

iShares Biotechnology ETF

VG Health

iShares US Pharma

iShares Global Healthcare

Defiance Daily Target 2X Long NVO ETF

Direxion S&P Biotech Bull 3X

Direxion Daily AMZN Bull 2X Shares

AST SpaceMobile

Rakuten Group, Inc.

CMS To Offer Wegovy To Eligible Medicare Patients At $50 Monthly Copay Starting July 2026